Jung Hoon Lee

Jung Hoon Lee

Auto-generated profile, based on publicly available information

Jung Hoon Lee


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JLJung Hoon Lee
Jung Hoon Lee
JJJun Hyoung Jeon
Jun Hyoung Jeon
Min Jae LeeMin Jae Lee
Min Jae Lee
One of the characteristic features of aging is the progressive loss of muscle mass, a nosological syndrome called sarcopenia. It is also a pathologic risk factor for many clinically adverse outcomes in older adults. Therefore, delaying the loss of muscle mass, through either boosting muscle protein synthesis or slowing down muscle protein degradation using nutritional supplements could be a compelling strategy to address the needs of the world’s aging population. Here, we review the recently identified properties of docosahexaenoic acid (DHA). It was shown to delay muscle wasting by stimulating intermediate oxidative stress and inhibiting proteasomal degradation of muscle proteins. Both the ubiquitin–proteasome and the autophagy–lysosome systems are modulated by DHA. Collectively, growing evidence indicates that DHA is a potent pharmacological agent that could improve muscle homeostasis. Better understanding of cellular proteolytic systems associated with sarcopenia will allow us to identify novel therapeutic interventions, such as omega-3 polyunsaturated fatty acids, to treat this disease.

29 March 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
LLLy Thi Huong Luu Le
Ly Thi Huong Luu Le
JLJeeyoung Lee
Jeeyoung Lee
DIDongjoon Im
Dongjoon Im
SPSunha Park
Sunha Park
KHKyoung-Doo Hwang
Kyoung-Doo Hwang
Min Jae LeeMin Jae Lee
Min Jae Lee
In tauopathic conditions, such as Alzheimer's disease (AD), highly soluble and natively unfolded tau polymerizes into an insoluble filament; however, the mechanistic details of this process are not clear. In AD brains, only a small segment of tau forms -helix-stacked protofilaments, while its flanking regions form disordered fuzzy coats. Here, we demonstrated that the tau AD nucleation core (tau-AC) sufficiently induced self-aggregation and recruited full-length tau to filaments. Unexpectedly, phospho-mimetic forms of tau-AC (at Ser324 or Ser356) showed markedly reduced aggregation and seeding propensities. Biophysical analysis revealed that the N-terminus of tau-AC facilitated the fibrillization kinetics, while its phosphorylation induced conformation changes, sterically shielding the nucleation motif. Tau-AC oligomers were efficiently internalized into cells via endocytosis and induced endogenous tau aggregation. In primary hippocampal neurons, tau-AC impaired axon initial segment plasticity upon chronic depolarization and was mislocalized in the somatodendritic compartments. Furthermore, we observed significantly impaired memory retrieval in mice intrahippocampally injected with tau-AC fibrils, which corresponded to the neuropathological staining and neuronal loss in the brain. These findings identified tau-AC species as a key neuropathological driver in AD, suggesting novel strategies for therapeutic intervention.